A.forall
A.forall is a Belgian-headquartered specialty pharmaceutical group that develops, licenses and commercializes generic and value-added injectable medicines for hospitals and clinics in Europe and the United States. It generates revenue through licensing deals, royalties, and direct product sales via its US subsidiary Milla Pharmaceuticals.
- Company typePrivate
- Founded2006
- HeadquartersAnderlecht, Belgium
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What A.forall does
A.forall is a Belgian-headquartered specialty pharmaceutical group that develops, licenses and commercializes generic medicines, with a particular focus on injectable generics and value-added formulations for hospital and clinical use. The company's portfolio spans 35+ molecules marketed across Europe and the United States, supported by 250+ distribution and licensing agreements with leading pharmaceutical companies. A.forall's US operations are conducted primarily through its subsidiary Milla Pharmaceuticals, which has secured multiple FDA ANDA approvals — including first-cycle approvals (a feat achieved by fewer than 15% of ANDA submissions) — and CGT exclusivity awards for products such as Tromethamine Injection and Sodium Acetate Injection. The company has also begun shifting from a partnership-only commercialization model to direct US launches under its own label, starting with Tromethamine Injection in January 2025.
A.forall generates revenue through one-time licensing deals, ongoing royalties, and direct product sales of generic pharmaceuticals targeting drug shortages and cost containment in healthcare systems. Distribution in the US is executed through a mix of exclusive commercialization partners (Sandoz, Woodward Pharma, Avenacy, Sagent Pharmaceuticals, Acella Pharmaceuticals) and direct channels, while historically European pharmacy distribution was handled via The Pharmacy House business — divested to Abacus Medicine in September 2025 to sharpen the company's focus on 100% generics. The company is majority-owned by The Riverside Company (since 2017), employs 144 people worldwide as of its September 2023 rebrand, and operates from Belgium with offices in Ireland (Balbriggan) and the United States (White Bear Lake, Minnesota). Recent strategic activity — including the September 2025 acquisition of four FDA-approved injectable generics and two pipeline assets from Provepharm's US portfolio, the October 2025 joint venture BRAFMed Lda with Nanoform and IMGA for nanoformulated oncology, and the appointment of Steen Vangsgaard as CEO — signals an accelerating pivot toward differentiated value-added generics and direct US market capture.
A.forall firmographics
Firmographics- Name
- A.forall
- Legal name
- A.forall Group
- Website
- https://aforallpharma.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- A.forall is a Belgian-headquartered specialty pharmaceutical group that develops, licenses and commercializes generic and value-added injectable medicines for hospitals and clinics in Europe and the United States. It generates revenue through licensing deals, royalties, and direct product sales via its US subsidiary Milla Pharmaceuticals.
- Ownership category
- akta.pro rank
A.forall industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
- akta.pro secondary industry
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where A.forall is headquartered
LocationHeadquarters
- HQ city
- Anderlecht
- HQ country
- Belgium
- HQ region
- Europe
Offices3 records
Markets served
A.forall business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Generic Drug Development and Commercialization: Developing and launching value-added generic pharmaceuticals including injectable generics covering various therapeutic areas. Portfolio of 35+ molecules marketed in Europe and the US.
- Licensing and Distribution Deals: 250+ distribution and licensing deals signed with leading pharmaceutical companies worldwide for development, registration and commercialization of generic products.
- US Market Product Launches: Direct commercialization and launch of FDA-approved generic injectable products in the US market, including recent acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US portfolio.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
A.forall product offering
Product offeringCore offering
A.forall develops, reformulates, and distributes generic pharmaceutical products with a primary focus on injectable generics and value-added medicines. The company operates through third-party manufacturers and commercialization partners, holding a portfolio of 35+ molecules marketed in Europe and the US. The core business addresses drug shortages in US and European markets through licensing and distribution agreements with leading pharmaceutical companies.
Product overview
A.forall is a global specialty pharma group focused entirely on the development, licensing, and commercialization of generic medicines. The company's core offering is its Generics Business, which develops value-added injectable generics and high-barrier generics. The portfolio includes 35+ molecules marketed in Europe and the US, supported by 250+ distribution and licensing deals with leading pharma companies. Key subsidiaries include Milla Pharmaceuticals (US-focused injectable generics developer and commercializer), and EcoPharmaSupply (Belgian pharmaceutical distributor). In 2025, A.forall acquired four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US portfolio. The company also co-develops nanoformulated medicines through BRAFMed Lda (with Nanoform and IMGA), including Nanoencorafenib. A.forall is headquartered in Belgium with offices in Ireland and the US. As of September 2025, the company sold its Pharmacy House (Retail & Hospital) business to Abacus Medicine to sharpen focus exclusively on generics. The company was rebranded from Alter Pharma Group to A.forall in September 2023.
Differentiator
Problem solved
Functional benefit
Brands
- Milla Pharmaceuticals: US subsidiary focused on development, licensing, acquisition and commercialization of generic prescription drugs for the US market, particularly niche injectable and solution products for hospitals and clinics.
- Neogen
- EcoPharmaSupply
Products and services
- A.forall Generics Business The core generics business of A.forall focused on developing, licensing, and commercializing value-added generic pharmaceuticals and injectable generics globally for hospital, clinical and pharmaceutical partner buyers. Includes a portfolio of 35+ molecules marketed in Europe and the US covering various therapeutic areas.
- Generic Injectable Acetaminophen/Paracetamol IV Generic injectable acetaminophen (paracetamol IV) launched in the US through commercialization partner Sandoz. Indicated for mild to moderate pain, severe pain with opioid analgesics, and fever reduction in adult and pediatric patients. The first US market entry for A.forall.
- Sodium Acetate Injection 2MEQ/mL Generic version of Sodium Acetate Injection 2MEQ/mL commercialized through exclusive partner Woodward Pharma Services LLC in the US market. Used as a source of sodium and as an additive in IV fluid mixes. Garnered 180-day CGT Exclusivity.
- Sodium Acetate Injection 4 mEq/mL Higher concentration supplemental ANDA (sANDA) product of Sodium Acetate Injection 4 mEq/mL, marketed by Fresenius Kabi USA LLC and commercialized through Woodward Pharma Services. Used for sodium supplementation in IV fluids and custom IV mixes.
- Magnesium Sulfate in Water for Injection Generic version of Magnesium Sulfate in Water for Injection in Non-PVC, Single-Patient Use Containers. Indicated for prevention and control of seizures in preeclampsia and eclampsia. Commercialized through US partners including Avenacy and Athenex Pharmaceuticals.
- Dexmedetomidine Hydrochloride Injection Generic version of Precedex (Dexmedetomidine Hydrochloride Injection) launched in partnership with Sagent Pharmaceuticals in the US. Available in 200 mcg per 50 mL and 400 mcg per 100 mL glass bottles for sedation of intubated and mechanically ventilated ICU patients.
- Tromethamine Injection Generic version of THAM (Tromethamine Injection) commercialized under A.forall's own label. Indicated for prevention and correction of metabolic acidosis. First product commercialized under A.forall's own label with coveted Competitive Generic Therapy (CGT) exclusivity.
- Pyridostigmine Bromide Syrup 60 mg/5mL Generic version of Mestinon (Pyridostigmine Bromide Syrup) 60 mg/5mL commercialized in partnership with Acella Pharmaceuticals LLC in the US. Indicated for symptomatic treatment of myasthenia gravis.
- Combogesic IV Groundbreaking IV painkiller combining paracetamol and ibuprofen, distributed by A.forall. First Belgian sales achieved in December 2023 with reimbursement granted by health authorities.
- Nanoencorafenib (BRAFMed Lda) Nanoformulated version of encorafenib (a targeted oncology treatment) developed in partnership with Nanoform and IMGA through the joint venture BRAFMed Lda. Aims to significantly reduce pill burden through higher drug-load formulation using Nanoform's proprietary technology. Currently in clinical development stage.
- Provepharm US Portfolio (4 FDA-approved injectable generics + 2 late-stage pipeline assets) Four FDA-approved injectable generics and two late-stage pipeline assets acquired from Provepharm's US portfolio. Significantly expanded A.forall's marketed portfolio in the US and supports renewed focus on generics business.
Quantifiable outcome
- 460,000 months of missing treatments delivered to Belgian pharmacies
- +2 more outcomes
Companies that use A.forall
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
A.forall technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
A.forall partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- NanoformcoreA.forall partnered with Nanoform and IMGA to develop and commercialize Nanoencorafenib, a nanoformulated version of encorafenib for oncology treatment. The three parties jointly founded BRAFMed Lda to lead clinical development and future outlicensing. Nanoform's proprietary technology enables higher drug-load formulations reducing pill burden for patients.
- IMGAcorePartnership with Nanoform and A.forall to develop and commercialize Nanoencorafenib through jointly founded BRAFMed Lda for clinical development and outlicensing of the oncology treatment.
- BRAFMed LdacoreJoint venture company founded by A.forall, Nanoform, and IMGA to lead clinical development and future outlicensing of Nanoencorafenib, a nanoformulated oncology treatment.
- Erik LazarichminorUS team member who will attend CPHI Frankfurt 2025 to discuss licensing, partnerships and expansion strategies across the Atlantic.
- Siddarth NirmalminorUS team member who will attend CPHI Frankfurt 2025 to discuss licensing, partnerships and expansion strategies across the Atlantic.
- Abacus MedicinecoreA.forall sold its Retail & Hospital (R&H) business unit (The Pharmacy House) to Abacus Medicine, a pharmaceutical company specializing in parallel distribution across Europe. Abacus Medicine has over 1,500 employees and EUR 1,487 million revenue in 2024, with sales in 35 countries. Transaction expected to close before year-end 2025.
- ProvepharmcoreA.forall acquired four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US portfolio. This acquisition significantly expands A.forall's US generics portfolio as part of its renewed focus on generics.
- Sagent PharmaceuticalscorePartnership with Sagent Pharmaceuticals for launch of generic version of Precedex (Dexmedetomidine Hydrochloride Injection) in the US market, addressing ongoing drug shortages for sedation in intubated patients.
- AvenacycoreAvenacy serves as the marketing partner for Magnesium Sulfate in Water for Injection in the US market. A.forall works with Avenacy to introduce the product to hospitals nationwide for improved patient care.
- Acella Pharmaceuticals LLCcorePartnership with Acella Pharmaceuticals for commercialization of generic version of Mestinon (Pyridostigmine Bromide Syrup) 60mg/5mL for treatment of myasthenia gravis in the US market.
- Athenex Pharmaceuticals DivisioncoreAthenex Pharmaceuticals serves as the marketing partner supplying Magnesium Sulfate in Water for Injection manufactured by SM Farmaceutici to the US market through GPI distribution.
- Woodward Pharma Services LLCcoreExclusive partnership for commercialization of Sodium Acetate Injection 2MEQ/mL in the US market. Woodward Pharma established first commercial sale through its partner network. Also received 180-day CGT Exclusivity from FDA.
- SandozcoreSandoz launched generic injectable acetaminophen (paracetamol IV) developed by Milla Pharmaceuticals, marking the first US launch of an Alter Pharma product. Sandoz serves as the exclusive commercialization partner for this product in the US market.
- KoningsminorAward-nominated co-packing company partnership for production and distribution of Alter Care Protect premium hand sanitizer. Previously donated 21,000 bottles of alcohol-based gel to Belgian pharmacies and collaborated on humanitarian hand sanitizer donations.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
A.forall competitors and assessment
Company assessmentBroad incumbents
- Apotex: Apotex is one of Canada's largest generic pharmaceutical manufacturers with a portfolio spanning sterile injectables, oral solids, and biosimilars. Comparable to A.forall in generic medicine development and commercialization, though Apotex has vertically integrated manufacturing.
- Hospira (Pfizer): Hospira, now part of Pfizer's Hospital business, was the dominant US sterile injectable generics manufacturer. Comparable to A.forall in the injectable generics space, but operates as a broad incumbent with full vertical integration and a much larger portfolio.
- Viatris: Viatris is a global generics and specialty pharma major formed from Mylan and Upjohn. Its broad portfolio across multiple dosage forms and geographies overlaps with A.forall's generic medicine focus, but Viatris operates at far greater scale and is a broad incumbent.
- Sandoz: Sandoz is the world's largest generics company and the exclusive US commercialization partner for A.forall's injectable acetaminophen. It is comparable as a broad incumbent in generic pharmaceuticals with deep injectable infrastructure, but operates at vastly greater scale than A.forall.
- Aurobindo Pharma: Aurobindo is a major India-based generic manufacturer with a growing US injectables franchise through Eugia. Comparable to A.forall as a generic injectable producer with global distribution, though Aurobindo owns large-scale manufacturing assets unlike A.forall's asset-light model.
- Teva Pharmaceutical Industries: Teva is one of the largest global generic pharmaceutical companies with a significant injectable and complex generics portfolio. It competes with A.forall on hospital injectable molecules but operates as a broad incumbent across many therapeutic areas and geographies.
Regional players
- Aspen Pharmacare: Aspen is a South African-headquartered specialty pharmaceutical company with a meaningful sterile injectable generics franchise serving emerging markets. Comparable to A.forall in injectable generic development and licensing, but Aspen's geographic focus is largely outside A.forall's core US/EU footprint.
Emerging players
- Alvotech: Alvotech is a biosimilars-focused specialty pharma company targeting hospital-administered biologics. While focused on biosimilars rather than small-molecule generics, it is comparable to A.forall as a focused specialty injectable developer pursuing regulatory exclusivity and complex formulations.
Direct peers
- Hikma Pharmaceuticals: Hikma is a UK-listed specialty generic injectables company with a US-focused hospital franchise. Like A.forall, Hikma emphasizes complex injectable generics, hospital-channel distribution, and value-added formulations, making it one of the closest direct comparables.
- Provepharm: Provepharm is a French specialty sterile injectable company whose US portfolio (4 FDA-approved generics + 2 late-stage assets) was acquired by A.forall in September 2025. Highly comparable as a specialty injectable generic peer focused on hospital shortage products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
A.forall social profiles
Digital presenceA.forall compliance and trust
Trust signalCompliance3 records
A.forall financial estimates
Financial estimateRevenue estimate
Valuation estimate
A.forall leadership team
Management profileNumber of profiles
Profiles14 records
A.forall subsidiaries and ownership
Company hierarchySubsidiaries4 records
A.forall funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
A.forall M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about A.forall
What does A.forall do?
A.forall develops, reformulates, and distributes generic pharmaceutical products with a primary focus on injectable generics and value-added medicines. The company operates through third-party manufacturers and commercialization partners, holding a portfolio of 35+ molecules marketed in Europe and the US. The core business addresses drug shortages in US and European markets through licensing and distribution agreements with leading pharmaceutical companies.
Is A.forall a public or private company?
A.forall is a private company. It is classified as private equity controlled and is currently operating.
When was A.forall founded?
A.forall was founded in 2006. It employs 101 to 250 people.
Where is A.forall based?
A.forall is headquartered in Anderlecht, Belgium, in the Europe region.
How does A.forall make money?
Three revenue lines are on record. Generic Drug Development and Commercialization is the primary driver. The others are licensing and Distribution Deals and US Market Product Launches.
Who are A.forall's main competitors?
Broad incumbents on record are Apotex, Hospira (Pfizer), Viatris, Sandoz, Aurobindo Pharma and Teva Pharmaceutical Industries. Aspen Pharmacare is listed as a regional player. Alvotech is listed as an emerging player. Direct peers are Hikma Pharmaceuticals and Provepharm.
Does A.forall have an API?
No public API is recorded for A.forall.
What industry is A.forall in?
A.forall's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 32541 and its SIC code is 2834.